Compare CLMB & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLMB | AQST |
|---|---|---|
| Founded | 1982 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 620.7M | 529.4M |
| IPO Year | 1996 | 2007 |
| Metric | CLMB | AQST |
|---|---|---|
| Price | $42.16 | $3.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $47.67 | $9.33 |
| AVG Volume (30 Days) | 198.8K | ★ 2.3M |
| Earning Date | 10-28-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.29 | N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $652,517,000.00 | $67,430,000.00 |
| Revenue This Year | $22.92 | $11.13 |
| Revenue Next Year | N/A | $40.69 |
| P/E Ratio | $46.24 | ★ N/A |
| Revenue Growth | ★ 40.14 | 0.77 |
| 52 Week Low | $15.25 | $2.94 |
| 52 Week High | $79.12 | $6.74 |
| Indicator | CLMB | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 64.01 | 45.61 |
| Support Level | $19.52 | $3.59 |
| Resistance Level | $44.89 | $4.34 |
| Average True Range (ATR) | 2.29 | 0.24 |
| MACD | -0.08 | 0.03 |
| Stochastic Oscillator | 60.60 | 62.50 |
Climb Global Solutions Inc is a cloud-based, value-added IT distribution and solutions company specializing in emerging technologies. It operates across the USA, Canada, United Kingdom, and Europe through multiple business units, including Climb Channel Solutions, Sigma, Grey Matter, Interwork, and TechXtend. The company is organized into two reportable operating segments. The Distribution segment distributes technical software to corporate resellers, value-added resellers (VARs), consultants, and systems integrators under the name Climb Channel Solutions. The Solutions segment is a cloud solutions provider and value-added reseller of software, hardware, and services to customers under the name Grey Matter.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.